Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2826
-0.0252-8.19%
Post-market: 0.28710.0045+1.59%19:59 EDT
Volume:2.03M
Turnover:595.39K
Market Cap:12.54M
PE:-0.17
High:0.3140
Open:0.3077
Low:0.2793
Close:0.3078
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.28
T/O Rate:4.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.51
PE(LYR):-0.15

Loading ...

VistaGen appoints Angel Angelov as chief medical officer

Reuters
·
May 19

Vistagen Appoints Angel S. Angelov, Md, MBA, as Chief Medical Officer

THOMSON REUTERS
·
May 19

VistaGen reports positive fasedienol data in PALISADE-3 open-label extension study

Reuters
·
May 12

Vistagen Therapeutics Inc - Palisade-4 Topline Data Expected in Q2 2026

THOMSON REUTERS
·
May 12

Vistagen Therapeutics Inc - Fasedienol Nasal Spray Well-Tolerated With No New Safety Findings After 12 Months

THOMSON REUTERS
·
May 12

Vistagen Therapeutics Inc - No Serious Adverse Events Related to Fasedienol Reported

THOMSON REUTERS
·
May 12

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of Palisade-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
May 12

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
May 09

BRIEF-Vistagen Announces Completion Of Last Patient Visit In Palisade-4 Phase 3 Public Speaking Challenge Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder

Reuters
·
May 08

VistaGen completes last patient visit in PALISADE-4 Phase 3 fasedienol trial

Reuters
·
May 08

Vistagen Therapeutics Inc - Open Label Extension of Palisade-4 Study Remains Ongoing

THOMSON REUTERS
·
May 08

Vistagen Therapeutics Inc - Topline Results for Palisade-4 Randomized Portion Expected in Q2 2026

THOMSON REUTERS
·
May 08

VistaGen says FDA clears refisolone IND to proceed with Phase 2 studies

Reuters
·
Apr 29

AbCellera target is profile more attractive than Vistagen, says JonesResearch

TIPRANKS
·
Apr 22

VistaGen says FDA clears Phase 2 refisolone study for menopausal hot flashes

Reuters
·
Apr 22

Vistagen Receives FDA “Study May Proceed” Letter Under Its Refisolone Ind Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) Due to Menopause

THOMSON REUTERS
·
Apr 22

Vistagen Therapeutics Inc - FDA Letter Enables Further Phase 2 Development of Refisolone in the U.S.

THOMSON REUTERS
·
Apr 22

VistaGen Therapeutics Grants Broad Employee Retention Stock Options

TIPRANKS
·
Apr 14

VistaGen grants retention stock options to executives at $0.54 per share

Reuters
·
Apr 14

VistaGen flags Nasdaq noncompliance after audit committee falls below three members

Reuters
·
Apr 03